# OnCo record encorafenib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/encorafenib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "encorafenib" ;
  schema:name "Encorafenib"@en ;
  schema:description "Encorafenib is a BRAF inhibitor that, with cetuximab and chemotherapy, became first-line standard for BRAF-mutant colorectal cancer in 2026."@en ;
  schema:url <https://onco.cc/drugs/encorafenib/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Encorafenib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q15409405> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Encorafenib>, <https://www.nice.org.uk/guidance/ta668>, <https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi>, <https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications> ;
  onco:status "approved" ;
  onco:modality "Small-molecule kinase inhibitor (BRAF)" ;
  schema:alternateName "Braftovi" ;
  onco:approval "US 2018: BRAF V600 melanoma with binimetinib", "US 2020: BRAF V600E mCRC with cetuximab, previously treated", "US 2026: First-line BRAF V600E mCRC with cetuximab and chemotherapy", "US 2024: Metastatic colorectal cancer with a BRAF V600E mutation, with cetuximab and mFOLFOX6, previously untreated", "US 2026: Metastatic colorectal cancer with a BRAF V600E mutation", "EU 2018: BRAF V600E-mutant metastatic colorectal cancer, with cetuximab", "England (NICE) 2021: BRAF V600E mutation-positive metastatic colorectal cancer after previous systemic treatment, with cetuximab" ;
  onco:acceleratedApproval "US 2024-12-20: In combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test" ;
  onco:acceleratedApprovalConfirmed "US 2026-02-24: In combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test" ;
  onco:related <https://onco.cc/biomarkers/braf-v600e/> ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/braf-v600e-colorectal/>, <https://onco.cc/cancers/braf-v600e-nsclc/>, <https://onco.cc/cancers/braf-v600-melanoma/>, <https://onco.cc/cancers/advanced-melanoma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/braf/>, <https://onco.cc/targets/egfr/> ;
  onco:companies <https://onco.cc/companies/pfizer/> ;
  onco:trials <https://onco.cc/trials/nct05270044/>, <https://onco.cc/trials/nct04657991/>, <https://onco.cc/trials/nct05217446/>, <https://onco.cc/trials/nct05195632/>, <https://onco.cc/trials/swog-s1406/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-venderbosch-mmr-braf-metastatic-colorectal-pooled-ccr-2014/>, <https://onco.cc/key-papers/paper-jones-non-v600-braf-colorectal-jco-2017/> .